ClinicalTrials.gg
Active, not recruitingNCT06945627VIRAL-MIUpdated Nov 5, 2026

Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections

An observational study in Severe Mental Illness, Inflammation and Viral Infections, sponsored by Sara Poletti. Active, not recruiting at 4 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Sara Poletti · Observational

How we know

Updated Nov 5, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
408,551
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This observational study aims to identify the underlying neurobiological and environmental mechanisms that influence vulnerability or resilience to mental illness in the context of infection and their contribution to severe infective outcomes in people with pre-existing mental illness. The main questions it aims to answer are:

  • How do viral infections influence the development of mental illness?
  • What neurobiological and environmental factors contribute to influence the development of mental illness following infection?
  • How do these factors relate to the severity of infectious illness in people with pre-existing mental disorders?

Researchers will move from large population databases to well-defined, deeply characterised samples to explore the association between infection and subsequent mental health outcomes, and the biological mechanisms behind these changes.

Participants's data has already been collected.

02

Conditions studied

  • Severe Mental Illness
  • Inflammation
  • Viral Infections
  • Mood Disorders
  • Schizophrenia
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's enrollment of 408,551 is above the median of 220 across 391 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

This is the only study on the registry with Sara Poletti as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with major depressive disorder or bipolar disorder (MOOD-MI cohort) and patients with COVID-19 (COVID-MI cohort). For epidemiological cohorts (MoBa, TOP, CHS) any patients with severe mental illnesses

Eligibility criteria

Inclusion Criteria for the MOOD-MI cohort:

  • A depressive episode according to (DSM-5) criteria in the course of MDD or BD with:

    • HDRS score > 17
    • Age 18-65 years;
  • Signed , able to understand, speak and write the national language

Inclusion Criteria for the COVID-MI cohort:

  • Having a positive nasopharyngeal swab for COVID-19 in the last 36 months;
  • Age between 18-25 years;
  • Signed informed consent, able to understand, speak and write the national language

Exclusion Criteria for the MOOD-MI cohort:

  • History of schizophrenia, schizoaffective disorder, psychosis not otherwise specified; anorexia or bulimia nervosa;
  • Taking following medications: antipsychotics, anticonvulsants, mood stabilizers; stimulants
  • Active infection requiring antibiotics therapy;
  • patient or other chronic diseases
  • Signs of active infection requiring treatment
  • Use of anti-inflammatory medication on a regular basis for a chronic inflammatory/ Disorder. Forbidden treatment: , Non Steroidal Anti-inflammatory Drugs, immunosuppressant IV-Ig based treatment
  • Ongoing fever, infection treated by antibiotics or uncontrolled diabetes type I or II;
  • Existing cancer or history of cancer in the last 5 years (except skin epidermoid cancer or in-situ cervix cancer);
  • Known infection or clinically manifest Acquired Immune Deficiency Syndrome (AIDS), Parkinson's or Alzheimer's disease, or any other serious condition likely to interfere e with the conduct of the trial;
  • Abuse of drugs or alcohol in the past 6 months

Exclusion Criteria for the COVID-MI cohort:

  • Comorbidity for psychotic disorders, verified by SCID-CV;
  • Current and substance use disorder;
  • Current comorbidity with neurological conditions or severe head trauma, general brain disorder preceding the emergence of PASC, including microhaemorrhages and/or ischaemia occurring during the acute phase of COVID;
  • Neuropsychological diagnosis of intellectual disability;
  • Presence of to blood sampling and/or MRI;
  • Pregnancy status at the time of recruitment.

Other exclusion criteria related to the MRI procedure include:

  • Aneurysm clip
  • Implanted neural stimulator
  • Implanted cardiac pacemaker or auto-defibrillator
  • Cochlear implant
  • Ocular foreign body (e.g., metal shavings)
  • Any implanted device (pumps, infusion devices, etc)
  • Shrapnel injuries.

For epidemiological cohorts (MoBa, TOP, CHS) age between 18 and 65 ya, diagnosis of a severe mental illness (Schizophrenia, Major Depression, Bipolar disorder, anxiety disorders),

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
408,551 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Trans-D

    Other: This research doesn't involve any kind of intervention on the study participants

  • Cov-N-Psy

    Other: This research doesn't involve any kind of intervention on the study participants

  • CHS1

    Other: This research doesn't involve any kind of intervention on the study participants

  • CHS2

    Other: This research doesn't involve any kind of intervention on the study participants

  • MOOD-MI

    Other: This research doesn't involve any kind of intervention on the study participants

  • COVID-MI

    Other: This research doesn't involve any kind of intervention on the study participants

  • MoBa

    Other: This research doesn't involve any kind of intervention on the study participants

  • TOP

    Other: This research doesn't involve any kind of intervention on the study participants

Interventions

  • OtherThis research doesn't involve any kind of intervention on the study participants

    This research doesn't involve any kind of intervention on the study participants

06

What researchers measure

Primary outcomes

  1. number of hospital admission for mental illness after infection diagnosis

    number of onset or relapse of mental illness following infection

    Time frame: 3 years

  2. number of infections (Pathogen Burden Summary - PBS) in patients with mental illness

    number of samples positive for antibodies for viruses associated with Mental illness in the literature (IgG, expressed as AU/mL)

    Time frame: 3 years

Secondary outcomes

  1. Environmental risk and resilience factors for mental illness and severe outcomes

    socio-economic socio-demographic variables inflammatory markers levels, timing and type of infection,

    Time frame: 3 years

  2. Neurobiological risk and resilience factors for mental illnesses and severe outcomes

    differentially expressed gene between patients with high vs low Pathogen Burden Summary (PBS) with or without mental illness

    Time frame: 3 years

  3. Predictive risk models based on an individual biological and environmental signatures

    stratification of patients in risk and resilence clusters using unsupervised machine learning algorithms based on * history of infection * plasmatic concentrations of immune analytes; * metabolites of the kynurenine pathway; * Polygenic Risk Scores; * gene expression; * measures of brain structure * measures of early and recent stress

    Time frame: 3 years

  4. genes or proteins that might be modified using drugs

    target genes involved in severe and post-infectious MI.

    Time frame: 3 years

07

Study locations

4 sites
08

References and documents

Publications

  • Lalousis PA, Schmaal L, Wood SJ, Reniers RLEP, Barnes NM, Chisholm K, Griffiths SL, Stainton A, Wen J, Hwang G, Davatzikos C, Wenzel J, Kambeitz-Ilankovic L, Andreou C, Bonivento C, Dannlowski U, Ferro A, Lichtenstein T, Riecher-Rossler A, Romer G, Rosen M, Bertolino A, Borgwardt S, Brambilla P, Kambeitz J, Lencer R, Pantelis C, Ruhrmann S, Salokangas RKR, Schultze-Lutter F, Schmidt A, Meisenzahl E, Koutsouleris N, Dwyer D, Upthegrove R; PRONIA Consortium. Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biol Psychiatry. 2022 Oct 1;92(7):552-562. doi: 10.1016/j.biopsych.2022.03.021. Epub 2022 Apr 12. PubMed 35717212 ↗
  • Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016 Dec;21(12):1696-1709. doi: 10.1038/mp.2016.3. Epub 2016 Feb 23. PubMed 26903267 ↗
  • Zhang Y, Wang J, Ye Y, Zou Y, Chen W, Wang Z, Zou Z. Peripheral cytokine levels across psychiatric disorders: A systematic review and network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jul 13;125:110740. doi: 10.1016/j.pnpbp.2023.110740. Epub 2023 Mar 8. PubMed 36893912 ↗
  • Tylee DS, Sun J, Hess JL, Tahir MA, Sharma E, Malik R, Worrall BB, Levine AJ, Martinson JJ, Nejentsev S, Speed D, Fischer A, Mick E, Walker BR, Crawford A, Grant SFA, Polychronakos C, Bradfield JP, Sleiman PMA, Hakonarson H, Ellinghaus E, Elder JT, Tsoi LC, Trembath RC, Barker JN, Franke A, Dehghan A; 23 and Me Research Team; Inflammation Working Group of the CHARGE Consortium; METASTROKE Consortium of the International Stroke Genetics Consortium; Netherlands Twin Registry; neuroCHARGE Working Group; Obsessive Compulsive and Tourette Syndrome Working Group of the Psychiatric Genomics Consortium; Faraone SV, Glatt SJ. Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. Am J Med Genet B Neuropsychiatr Genet. 2018 Oct;177(7):641-657. doi: 10.1002/ajmg.b.32652. Epub 2018 Oct 16. PubMed 30325587 ↗
  • Shorter JR, Meijsen J, Nudel R, Krebs M, Gadin J, Mikkelsen DH, Nogueira Avelar E Silva R, Benros ME, Thompson WK, Ingason A, Werge T. Infection Polygenic Factors Account for a Small Proportion of the Relationship Between Infections and Mental Disorders. Biol Psychiatry. 2022 Aug 15;92(4):283-290. doi: 10.1016/j.biopsych.2022.01.007. Epub 2022 Jan 24. PubMed 35305821 ↗
  • Debost JPG, Thorsteinsson E, Trabjerg B, Benros ME, Albinana C, Vilhjalmsson BJ, Borglum A, Mors O, Werge T, Mortensen PB, Agerbo E, Petersen LV. Genetic and psychosocial influence on the association between early childhood infections and later psychiatric disorders. Acta Psychiatr Scand. 2022 Nov;146(5):406-419. doi: 10.1111/acps.13491. Epub 2022 Sep 8. PubMed 35999619 ↗
  • Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, Mortensen PB. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013 Aug;70(8):812-20. doi: 10.1001/jamapsychiatry.2013.1111. PubMed 23760347 ↗
  • Vai B, Parenti L, Bollettini I, Cara C, Verga C, Melloni E, Mazza E, Poletti S, Colombo C, Benedetti F. Predicting differential diagnosis between bipolar and unipolar depression with multiple kernel learning on multimodal structural neuroimaging. Eur Neuropsychopharmacol. 2020 May;34:28-38. doi: 10.1016/j.euroneuro.2020.03.008. Epub 2020 Mar 29. PubMed 32238313 ↗
  • Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011 Dec;168(12):1303-10. doi: 10.1176/appi.ajp.2011.11030516. PubMed 22193673 ↗
  • McGrath JJ, Pemberton MR, Welham JL, Murray RM. Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: a southern hemisphere study. Schizophr Res. 1994 Dec;14(1):1-8. doi: 10.1016/0920-9964(94)90002-7. PubMed 7893616 ↗
  • Mazza MG, Palladini M, Villa G, Agnoletto E, Harrington Y, Vai B, Benedetti F. Prevalence of depression in SARS-CoV-2 infected patients: An umbrella review of meta-analyses. Gen Hosp Psychiatry. 2023 Jan-Feb;80:17-25. doi: 10.1016/j.genhosppsych.2022.12.002. Epub 2022 Dec 7. PubMed 36535239 ↗
  • Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P; COVID-19 BioB Outpatient Clinic Study group; Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020 Oct;89:594-600. doi: 10.1016/j.bbi.2020.07.037. Epub 2020 Jul 30. PubMed 32738287 ↗
  • Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, Borsini A, Casanova Dias M, Tamouza R, Leboyer M, Benros ME, Branchi I, Fusar-Poli P, De Picker LJ. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17. PubMed 34274033 ↗
  • Vai B, Mazza MG, Marisa CD, Beezhold J, Karkkainen H, Saunders J, Samochowiec J, Benedetti F, Leboyer M, Fusar-Poli P, De Picker L. Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health. Eur Psychiatry. 2022 Aug 16;65(1):e47. doi: 10.1192/j.eurpsy.2022.2307. PubMed 35971656 ↗
  • De Picker LJ, Victoriano GM, Richards R, Gorvett AJ, Lyons S, Buckland GR, Tofani T, Norman JL, Chatelet DS, Nicoll JAR, Boche D. Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study. Brain Behav Immun. 2021 Oct;97:319-327. doi: 10.1016/j.bbi.2021.07.017. Epub 2021 Jul 30. PubMed 34339805 ↗
  • Tzur Bitan D, Krieger I, Kridin K, Komantscher D, Scheinman Y, Weinstein O, Cohen AD, Cicurel AA, Feingold D. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study. Schizophr Bull. 2021 Aug 21;47(5):1211-1217. doi: 10.1093/schbul/sbab012. PubMed 33604657 ↗
  • Mazza MG, Palladini M, De Lorenzo R, Bravi B, Poletti S, Furlan R, Ciceri F; COVID-19 BioB Outpatient Clinic Study group; Rovere-Querini P, Benedetti F. One-year mental health outcomes in a cohort of COVID-19 survivors. J Psychiatr Res. 2022 Jan;145:118-124. doi: 10.1016/j.jpsychires.2021.11.031. Epub 2021 Nov 22. PubMed 34894521 ↗
  • Poletti S, Vai B, Mazza MG, Zanardi R, Lorenzi C, Calesella F, Cazzetta S, Branchi I, Colombo C, Furlan R, Benedetti F. A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110136. doi: 10.1016/j.pnpbp.2020.110136. Epub 2020 Oct 9. PubMed 33045321 ↗
  • Poletti S, de Wit H, Mazza E, Wijkhuijs AJM, Locatelli C, Aggio V, Colombo C, Benedetti F, Drexhage HA. Th17 cells correlate positively to the structural and functional integrity of the brain in bipolar depression and healthy controls. Brain Behav Immun. 2017 Mar;61:317-325. doi: 10.1016/j.bbi.2016.12.020. Epub 2016 Dec 23. PubMed 28025071 ↗
  • Poletti S, Leone G, Hoogenboezem TA, Ghiglino D, Vai B, de Wit H, Wijkhuijs AJM, Locatelli C, Colombo C, Drexhage HA, Benedetti F. Markers of neuroinflammation influence measures of cortical thickness in bipolar depression. Psychiatry Res Neuroimaging. 2019 Mar 30;285:64-66. doi: 10.1016/j.pscychresns.2019.01.009. Epub 2019 Jan 29. PubMed 30785023 ↗
  • Benedetti F, Palladini M, Paolini M, Melloni E, Vai B, De Lorenzo R, Furlan R, Rovere-Querini P, Falini A, Mazza MG. Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study. Brain Behav Immun Health. 2021 Dec;18:100387. doi: 10.1016/j.bbih.2021.100387. Epub 2021 Nov 2. PubMed 34746876 ↗
  • Tzur Bitan D, Kridin K, Cohen AD, Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry. 2021 Oct;8(10):901-908. doi: 10.1016/S2215-0366(21)00256-X. Epub 2021 Aug 6. PubMed 34364406 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in May 2026, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 25, 2025
StartActual
May 2, 2024
Primary completionActual
May 2, 2026
CompletionEst.
Mar 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Belgium, 1 Israel, 1 Italy, 1 Norway)
  • University of Antwerp · Antwerp, Belgium
  • University of Haifa · Haifa, Israel
  • IRCCS Ospedale San Raffaele · Milan, Italy
  • University of Oslo · Oslo, Norway
Show 4 removed
  • University of Antwerp · Antwerp, Belgium
  • University of Haifa · Haifa, Israel
  • IRCCS Ospedale San Raffaele · Milan, Italy
  • University of Oslo · Oslo, Norway
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 Belgium, 1 Israel, 1 Italy, 1 Norway)
    • University of Antwerp · Antwerp, Belgium
    • University of Haifa · Haifa, Israel
    • IRCCS Ospedale San Raffaele · Milan, Italy
    • University of Oslo · Oslo, Norway
    Show 4 removed
    • University of Antwerp · Antwerp, Belgium
    • University of Haifa · Haifa, Israel
    • IRCCS Ospedale San Raffaele · Milan, Italy
    • University of Oslo · Oslo, Norway
    + 5 other changes: index terms, identifiers, verification date, date precision and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06945627
Lead sponsor
Sara Poletti
Responsible party
Sara Poletti (Principal Investigator, IRCCS San Raffaele) — Sponsor-investigator
First posted
Apr 25, 2025
Start date
May 2, 2024
Primary completion
May 2, 2026
Completion
Mar 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Sara Poletti, PhD
principal investigator · IRCCS Ospedale San Raffaele

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion